Alternative process for the preparation of losartan

Details Alternative process for the preparation of losartan Alternative process for the preparation of losartan

2011-04-12

2011-04-12

Chung, Susannah (Department: 1626)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

C548S252000

Reexamination Certificate

active

07923566

ABSTRACT:
The invention relates to an improved process for the preparation of Losartan. The process comprising reacting 2-n-butyl-4-chloro-5-formyl imidazole with 2-(4-bromomethyl) benzonitrile in the presence of a phase transfer catalyst and an alkali, and reducing the resulting cyano aldehyde to produce a cyano alcohol which is further reacted with sodium azide in N-methyl pyrrolidinone and a salt to produce Losartan.

REFERENCES:
patent: 5484995 (1996-01-01), Scofield et al.
patent: 6774241 (2004-08-01), Clark et al.
patent: 2010/0222597 (2010-09-01), Veera Reddy
patent: 0578125 (1994-01-01), None
patent: WO-9827081 (1998-06-01), None
patent: WO-9902502 (1999-01-01), None
patent: WO-9937623 (1999-07-01), None
patent: WO-9942465 (1999-08-01), None
patent: WO-0132646 (2001-05-01), None
patent: WO-02098878 (2002-12-01), None
patent: WO-03065046 (2003-08-01), None
patent: WO-03066056 (2003-08-01), None
patent: WO-03072548 (2003-09-01), None
patent: WO-2004035047 (2004-04-01), None
patent: WO-2004048328 (2004-06-01), None
patent: WO-2004048330 (2004-06-01), None
patent: WO-2004048331 (2004-06-01), None
patent: WO-2004055026 (2004-07-01), None
patent: WO 2005/014602 (2005-02-01), None
patent: WO-2005014602 (2005-02-01), None
Monsma, F. J., Jr. et al, “Cloning and Expression of a Novel . . . ”, Molecular Pharmacology, 1993, 43, 320-327, Am Society for Pharm and Experimental Therapeutics, USA.
Kohen, R. et al, “Cloning, Characterization, and Chromosomal . . . ”, Journal of Neurochemistry, 1996, 66, 47-56, Lippincott-Raven Publishers, USA.
Ruat, M. et al, “A Novel Rat Serotonin (5-HT6) Receptor . . . ”, Biochemical Biophysical Research Communications, 1993, 193, 268-276, Academic Press.
Ward, R. P. et al, “Localization of Serotonin Subtype 6 Receptor . . . ”, Neuroscience, 1995, 64, 1105-1111, Elsevier Science Ltd, UK.
Reavill, C. et al, “The Therapeutic Potential of 5-HT6 . . . ”, Current Opinion in Invesigational Drugs, 2001, 2(1):104-109, PharmaPress Ltd.
Gerard, C. et al, “Immuno-localization of serotonin 5-HT6 receptor-like material . . . ”, Brain Research, 1997, 746, 207-219, ,Elsevier Science B.V.
Bentley, J. C. et al, “Investigation of stretching behaviour induced by the selective . . . ”, British Journal of Pharmacology, 1999, 126 (7), 1537-1542, Stockton Press.
Dawson, L. A. et al, “In vivo effects of the 5-HT6 antagonist . . . ”, British Journal of Pharmacology, 2000, 130 (1), 23-26, Macmillan Publishers Ltd.
Rogers, D. C. et al, “The Selective 5HT6 Receptor Antagonist”, Society of Neuroscience, Abstracts, 2000, 26, 680, UK.
Ernst, M. et al, “DOPA Decarboxylase Activity in Attention Deficit . . . ”, Journal of Neuroscience, 1998, 18(15), 5901-5907, Society for Neuroscience, USA.
Branchek, T. A. et al, Annual Reviews in Pharmacology and Toxicology, 2000, 40, 319-334, Annual Reviews, USA.
Stean, T. et al, “Anticonvulsant Properties of the Selective 5-HT6 Receptor . . .” British Journal of Pharmacology, 1999, 127 Proc. Supplement-131P.
Routledge, C., “Characterization of SB-271046: A Potent . . . ”, British Journal of Pharamacology, 2000, 130, 1606-1612, Macmillan Publishers Ltd.
Roth, B.L. et al., “Binding of Typical and Atypical Agents . . . ”, Journ of Pharm and Experimental Therapeutics, 1994, 268, pp. 1403-1410, Am Society for Pharm and Exp. Ther.
Wooley, M.L. et al., “A Role for 5-HT6 Receptors in Retention of Spatial Learning . . . ”, Neuropharmacology, 2001, 41: 210-219, Elsevier Science Ltd.
Berge, Stephen et al., “Pharmaceutical Salts”, Journal of Pharmaceutical Sciences, 1977, 66, 1-19.
Kask, A. et al., “Neuropeptide Y Y5 Receptor Antagonist CGP71683A . . . ”, European Journal of Pharmacology, 414, 2001, 215-224, Elsevier Science B.V.
Turnbull, A. et. al., “Selective Antagonism of the NPY Y5 Receptor Does Not . . . ”, Diabetes, 51, 2002, 2441-2449.
Ennaceur, A. et al, “A New One-trial Test for Neurobiological Studies of Memory . . . ”, Behavioural Brain Research, 1988, 31, 47-59, Elsevier Science Publishers.
King, M. V. et. al., “5-HT6 Receptor Antagonists Reverse Delay-dependent . . . ”, Neuropharmacology, 2004, 47, 195-204, Elsevier Ltd.
Yamada, N. et al., “Improvement of Scopolamine-induced Memory Impairment . . . ”, Pharmacology, Biochem. And Behaviour, 2004, 78, 787-791, Elsevier Inc.
Linder, M. D. et al., “An Assessment of the Effects of Serotonin 6 . . . ”, Journal of Pharm and Exp. Ther., 2003, 307 (2), 682-691, Am Soc. for Pharm and Exp. Ther., USA.
Callahan, P. M. et al., “Characterization of the Selective 5-HT6 Receptor . . . ”, Abstract, 776.19.2004, Society for Neuroscience, 2004.
Fox, G. B. et al., “Memory Consolidation Induces a Transient and . . . ”, Journal of Neurochemistry, 1995, 65, 6, 2796-2799, Lippincott-Raven Publishers, USA.
Carini, D.J. et al., Nonpeptide Angiotensin II Receptor Antagonists . . . :, Journal of Medicinal Chemistry, 1991, 34, 2525-2547, American Chemical Society, USA.

Affiliated with

Also associated with

Rating

Alternative process for the preparation of losartan does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Alternative process for the preparation of losartan, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Alternative process for the preparation of losartan will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2640817